Anesthetic Cost Analysis With Desflurane in Automated Gas Control Mode
Anesthetic Cost Analysis With Desflurane in Automated Gas Control Mode With Maquet Flow-i Anaesthesia Machine
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Malatya, Turkey, 44280
- Inonu Univercity
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adult patients undergoing hepatectomy with general anesthesia
Exclusion Criteria:
- Essential data missing
- Patient participating in other research projects
- Drug allergy
- Anesthetic complication story
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Group 1
The patient who receive 300 mL fresh gas flow with AGC mode during the general anesthesia
|
|
Group 2
The patient who receive 600 mL fresh gas flow with AGC mode during the general anesthesia
|
|
Group 3
The patient who receive 600 mL fresh gas flow with manuelly during the general anesthesia
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Amount of used anesthetic gas (desflurane)
Time Frame: Through study completion, an average of 2 month
|
Amount of used desflurane will be determined in milliliter by anesthesia machine (Maquet Flow i40) for each patient.
|
Through study completion, an average of 2 month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Heart rate
Time Frame: Through study completion, an average of 2 month
|
Heart rate/min
|
Through study completion, an average of 2 month
|
|
Mean arterial pressure
Time Frame: Through study completion, an average of 2 month
|
Mean arterial pressure (mm/Hg)
|
Through study completion, an average of 2 month
|
|
Peripheral oxygen saturation
Time Frame: Through study completion, an average of 2 month
|
Peripheral oxygen saturation (%)
|
Through study completion, an average of 2 month
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Yusuf Z Çolak, MD, Investigator
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- Inonu uni
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Safety Issues
-
NCT05869357Not yet recruiting
-
NCT05523596Completed
-
NCT06494527Active, not recruiting
-
NCT06117800Completed
-
NCT04268758Withdrawn
-
NCT04491266Completed
-
NCT03908957Completed